← Back to Search

Biocellular Regenerative Therapy

Stem Cell and Growth Factor Therapy for Osteoarthritis (GARM-MSK-ALD Trial)

N/A
Recruiting
Research Sponsored by Healeon Medical Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented osteoarthritic inflammatory and/or degenerative changes in the joint or connective tissues of the knee, hip, shoulder, Achilles tendon, Sacroiliac Joint, wrist/hand, foot/ankle, or Plantar Fasciitis (PR)
Be older than 18 years old
Must not have
Medication or Opiate addition, or in active treatment for drug rehabilitation
Known active cancer, chemotherapy, or radiation therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 month, 6 months, 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying a new way to treat osteoarthritis by using a person's own stem cells and growth factors.

Who is the study for?
This trial is for adults with documented osteoarthritis who can follow treatment and tracking instructions. They must have enough donor tissue for the procedure, understand the consent form, and not have any systemic disorders that would make the procedures unsafe. People with active cancer, infections, drug addiction or severe brain injuries, pregnant women, high dose steroid users within six months before treatment are excluded.
What is being tested?
The study tests minimally invasive treatments using a patient's own stem cells plus HD-PRP to treat osteoarthritis without pharmaceuticals or traditional surgery. It compares different combinations of Tissue Stromal Vascular Fraction (tSVF), Cellular Stromal Vascular Fraction (cSVF), PRP Concentrate and saline solution in three arms.
What are the potential side effects?
Potential side effects may include discomfort at extraction and injection sites, infection risk from injections, allergic reactions to components used during treatment like PRP concentrate or normal saline solution.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have documented arthritis or tissue degeneration in my knee, hip, shoulder, Achilles tendon, Sacroiliac Joint, wrist/hand, foot/ankle, or have Plantar Fasciitis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not currently dealing with drug addiction or in rehab.
Select...
I am currently receiving treatment for active cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 month, 6 months, 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 month, 6 months, 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes from Baseline visual analog pain scale (VAS)
Changes in Ultrasound Images from Baseline Condition
Numeric Pain Rating Scale (NPRS)
+1 more
Secondary study objectives
Disabilities of the Arm, Shoulder, and Hand Score (DASH)
Foot and Ankle Ability Measure (FAAM)
Foot and Ankle Disability Index (FADI)
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: tSVF + PRP Arm1Experimental Treatment2 Interventions
Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate
Group II: tSVF + PRP + cSVF Arm 2Experimental Treatment3 Interventions
Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate + Cellular Stromal Vascular Fraction (cSVF)
Group III: Normal Saline IV + cSVF Arm 3Experimental Treatment2 Interventions
Cellular Stromal Vascular Fraction (cSVF); Sterile Normal Saline Intravenous (IV) Introduction

Find a Location

Who is running the clinical trial?

Healeon Medical IncLead Sponsor
8 Previous Clinical Trials
610 Total Patients Enrolled
Donna Alderman, DOUNKNOWN
Robert W. Alexander, MDUNKNOWN
3 Previous Clinical Trials
120 Total Patients Enrolled

Media Library

Cellular Stromal Vascular Fraction (cSVF) (Biocellular Regenerative Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04238143 — N/A
Osteoarthritis Research Study Groups: tSVF + PRP Arm1, tSVF + PRP + cSVF Arm 2, Normal Saline IV + cSVF Arm 3
Osteoarthritis Clinical Trial 2023: Cellular Stromal Vascular Fraction (cSVF) Highlights & Side Effects. Trial Name: NCT04238143 — N/A
Cellular Stromal Vascular Fraction (cSVF) (Biocellular Regenerative Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04238143 — N/A
Osteoarthritis Patient Testimony for trial: Trial Name: NCT04238143 — N/A
~26 spots leftby Sep 2026